Skip to content

Study · Animal study (in vivo) · rat · 1999

3 results

New model of cytoprotection/adaptive cytoprotection in rats: endogenous small irritants, antiulcer agents and indomethacin.

Sikirić P, Seiwerth S, Desković S, Grabarević Z, Marović A, Rucman R, Petek M, Konjevoda P, Jadrijević S, Sosa T, Perović D, Aralica G, Turković B

European journal of pharmacology1 Jan 1999Cited by 28 (Europe PMC)

PMID9920181 (opens in a new tab)DOI10.1016/s0014-2999(98)00818-8 (opens in a new tab)PepBankPUB-09920181
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with gastrojejunal anastomosis challenged with ethanol, BPC‑157 had mainly adaptive cytoprotective activity.

    In plain wordsIn rats, BPC‑157 protected the stomach mainly through adaptive protection against a later ethanol challenge.

    Peptide
    BPC-157
    Outcome
    DecreaseAdaptive cytoprotection in endogenous/exogenous irritant studies
    Study

    ratn: not reported in source

    gastrojejunal anastomosis and ethanol gastric lesion models
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg or 10 ngAs given in this study (rat).

    Source sentences

    Summary
    whereas pentadecapeptide BPC157 (10 microg or 10 ng), and omeprazole (10 mg) had mainly adaptive cytoprotective activity (endogenous/exogenous irritant studies)
    1 context sentence
    Summary · context
    Their effects were compared in rats treated as follows: exogenous irritant studies (96% or 20% ethanol), exogenous/exogenous irritant studies (20% ethanol 1 h before 96% ethanol), endogenous irritant studies (gastrojejunal anastomosis for 24 h), and endogenous/exogenous irritant studies (gastrojejun…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given two consecutive ethanol challenges, BPC‑157 had both cytoprotective and adaptive cytoprotective activities.

    In plain wordsIn rats, BPC‑157 gave both simple and adaptive stomach protection against repeated ethanol challenge.

    Peptide
    BPC-157
    Outcome
    DecreaseCytoprotective and adaptive cytoprotective activity in exogenous/exogenous irritant studies
    Study

    ratn: not reported in source

    gastrojejunal anastomosis and ethanol gastric lesion models
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg or 10 ngAs given in this study (rat).

    Source sentences

    Summary
    or both cytoprotective and adaptive cytoprotective activities (exogenous/exogenous irritant studies).
    1 context sentence
    Summary · context
    Their effects were compared in rats treated as follows: exogenous irritant studies (96% or 20% ethanol), exogenous/exogenous irritant studies (20% ethanol 1 h before 96% ethanol), endogenous irritant studies (gastrojejunal anastomosis for 24 h), and endogenous/exogenous irritant studies (gastrojejun…
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, BPC‑157 further reduced gastric lesions beyond the spontaneous lesion reduction of adaptive cytoprotection.

    In plain wordsIn rats, BPC‑157 reduced stomach lesions further than the stomach's own adaptive reduction.

    Peptide
    BPC-157
    Outcome
    DecreaseFurther lesion reduction beyond spontaneous reduction
    Study

    ratn: not reported in source

    gastrojejunal anastomosis and ethanol gastric lesion models
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg or 10 ngAs given in this study (rat).

    Source sentences

    Summary
    Both spontaneous lesion reduction, as an essential mechanism of adaptive cytoprotection, and the further lesion reduction by agents, such as pentadecapeptide BPC 157 and omeprazole

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.